Dr. John Michael Holland, MD

Dr. Holland practices at Adventist Health Portland in Portland, Oregon, part of Adventist Health.

Dr. Holland's NPI, 1104834662, was assigned on August 3, 2006. Dr. Holland graduated from Washington University School of Medicine in 1989. Dr. Holland holds Oregon license MD19074.

Dr. Holland's primary practice is Adventist Health Portland, at 10123 Se Market Street, Portland, OR 97216 in Multnomah County. The practice phone is (503) 257-2500.

Dr. Holland's primary practice is Adventist Health Portland in Portland, Oregon, part of Adventist Health. Dr. Holland is also affiliated with OHSU Hospital. The medical group on file is Adventist Health Portland. Dmand AI also links Dr. Holland to 1 more hospital and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holland practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Holland's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Holland is licensed in Oregon.

CMS data shows 153 Medicare services from Dr. Holland across 2 procedure codes in 2024, for 35 Medicare patients. Medicare paid $8,098 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Holland in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have cancer, and 69% have high blood pressure. Their average risk score is 1.49, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Holland's median patient age at 75, with 32% women.

In 2024, Dr. Holland wrote 40 Medicare Part D claims for 21 patients. 98% of them were for generic drugs. They cover 3 drugs, with $1,019 in total drug cost. In 2019, CMS named 93 claims across 4 drugs.

Dr. Holland accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 28 papers to Dr. Holland, published from 2002 to 2020. 2014 was the busiest year, with 3. The most frequent topics are Carcinoma, Squamous Cell, Esophageal Neoplasms and Head and Neck Neoplasms. Dr. Holland has published most often in Int J Radiat Oncol Biol Phys. Dr. Holland's most frequent co-authors are Nima Nabavizadeh, MD, David Alan Elliott, MD and Timur Mitin, MD, PhD.

Dmand AI links Dr. Holland to 3 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Salivary Gland Neoplasms, Stomatitis and Tobacco Use.

CMS Open Payments shows 5 general payments to Dr. Holland from 3 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $123.

Dr. Holland graduated from Washington University School of Medicine in 1989.